KIORA PHARMACEUTICALS INC — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2021-01-04

Reporting Person: Mann Brenda (VP of Research & Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-04	Common Stock	F	115	$4.85	Disposed	17256	Direct

Footnotes

F1: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2021.